Cannabis, a complex plant: different compounds and different effects on individuals

被引:374
作者
Atakan, Zerrin [1 ]
机构
[1] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, DeCrespigny Pk, London SE5 8AF, England
关键词
Cannabis; delta-9-tetrahydrocannabinol; cannabidiol; tetrahydrocannabivarin; endocannabinoids; individual sensitivity to cannabis;
D O I
10.1177/2045125312457586
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cannabis is a complex plant, with major compounds such as delta-9-tetrahydrocannabinol and cannabidiol, which have opposing effects. The discovery of its compounds has led to the further discovery of an important neurotransmitter system called the endocannabinoid system. This system is widely distributed in the brain and in the body, and is considered to be responsible for numerous significant functions. There has been a recent and consistent worldwide increase in cannabis potency, with increasing associated health concerns. A number of epidemiological research projects have shown links between dose-related cannabis use and an increased risk of development of an enduring psychotic illness. However, it is also known that not everyone who uses cannabis is affected adversely in the same way. What makes someone more susceptible to its negative effects is not yet known, however there are some emerging vulnerability factors, ranging from certain genes to personality characteristics. In this article we first provide an overview of the biochemical basis of cannabis research by examining the different effects of the two main compounds of the plant and the endocannabinoid system, and then go on to review available information on the possible factors explaining variation of its effects upon different individuals.
引用
收藏
页码:241 / 254
页数:14
相关论文
共 106 条
[71]   Regulation of nausea and vomiting by cannabinoids [J].
Parker, Linda A. ;
Rock, Erin M. ;
Limebeer, Cheryl L. .
BRITISH JOURNAL OF PHARMACOLOGY, 2011, 163 (07) :1411-1422
[72]   The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids:: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin [J].
Pertwee, R. G. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (02) :199-215
[73]   International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 [J].
Pertwee, R. G. ;
Howlett, A. C. ;
Abood, M. E. ;
Alexander, S. P. H. ;
Di Marzo, V. ;
Elphick, M. R. ;
Greasley, P. J. ;
Hansen, H. S. ;
Kunos, G. ;
Mackie, K. ;
Mechoulam, R. ;
Ross, R. A. .
PHARMACOLOGICAL REVIEWS, 2010, 62 (04) :588-631
[74]   Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists [J].
Pertwee, R. G. .
CURRENT MEDICINAL CHEMISTRY, 2010, 17 (14) :1360-1381
[75]   Pharmacology of cannabinoid CB1 and CB2 receptors [J].
Pertwee, RG .
PHARMACOLOGY & THERAPEUTICS, 1997, 74 (02) :129-180
[76]   The pharmacology of cannabinoid receptors and their ligands: an overview [J].
Pertwee, RG .
INTERNATIONAL JOURNAL OF OBESITY, 2006, 30 (Suppl 1) :S13-S18
[77]   Emerging strategies for exploiting cannabinoid receptor agonists as medicines [J].
Pertwee, Roger G. .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 156 (03) :397-411
[78]   Subjective effects of cannabis before the first psychotic episode [J].
Peters, Bart D. ;
de Koning, Pelle ;
Dingemans, Peter ;
Becker, Hiske ;
Linszen, Don H. ;
de Haan, Lieuwe .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2009, 43 (12) :1155-1162
[79]   Targeting dopamine D2 and Cannabinoid-1 (CB1) receptors in rat nucleus accumbens [J].
Pickel, VM ;
Chan, J ;
Kearn, CS ;
Mackie, K .
JOURNAL OF COMPARATIVE NEUROLOGY, 2006, 495 (03) :299-313
[80]   Potency of Δ9-THC and other cannabinoids in cannabis in England in 2005:: Implications for psychoactivity and pharmacology [J].
Potter, David J. ;
Clark, Peter ;
Brown, Marc B. .
JOURNAL OF FORENSIC SCIENCES, 2008, 53 (01) :90-94